171 related articles for article (PubMed ID: 22141583)
1. Phospho-ibuprofen (MDC-917) incorporated in nanocarriers: anti-cancer activity in vitro and in vivo.
Nie T; Wong CC; Alston N; Aro P; Constantinides PP; Rigas B
Br J Pharmacol; 2012 Jun; 166(3):991-1001. PubMed ID: 22141583
[TBL] [Abstract][Full Text] [Related]
2. A novel ibuprofen derivative with anti-lung cancer properties: synthesis, formulation, pharmacokinetic and efficacy studies.
Cheng KW; Nie T; Ouyang N; Alston N; Wong CC; Mattheolabakis G; Papayannis I; Huang L; Rigas B
Int J Pharm; 2014 Dec; 477(1-2):236-43. PubMed ID: 25311177
[TBL] [Abstract][Full Text] [Related]
3. Sterically stabilized liposomes incorporating the novel anticancer agent phospho-ibuprofen (MDC-917): preparation, characterization, and in vitro/in vivo evaluation.
Mattheolabakis G; Nie T; Constantinides PP; Rigas B
Pharm Res; 2012 Jun; 29(6):1435-43. PubMed ID: 22072052
[TBL] [Abstract][Full Text] [Related]
4. Pegylation improves the pharmacokinetics and bioavailability of small-molecule drugs hydrolyzable by esterases: a study of phospho-Ibuprofen.
Mattheolabakis G; Wong CC; Sun Y; Amella CA; Richards R; Constantinides PP; Rigas B
J Pharmacol Exp Ther; 2014 Oct; 351(1):61-6. PubMed ID: 25047517
[TBL] [Abstract][Full Text] [Related]
5. Phospho-ibuprofen (MDC-917) suppresses breast cancer growth: an effect controlled by the thioredoxin system.
Sun Y; Rowehl LM; Huang L; Mackenzie GG; Vrankova K; Komninou D; Rigas B
Breast Cancer Res; 2012 Jan; 14(1):R20. PubMed ID: 22293394
[TBL] [Abstract][Full Text] [Related]
6. Phospho-ibuprofen (MDC-917) is a novel agent against colon cancer: efficacy, metabolism, and pharmacokinetics in mouse models.
Xie G; Sun Y; Nie T; Mackenzie GG; Huang L; Kopelovich L; Komninou D; Rigas B
J Pharmacol Exp Ther; 2011 Jun; 337(3):876-86. PubMed ID: 21422165
[TBL] [Abstract][Full Text] [Related]
7. The Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib.
Korani M; Nikoofal-Sahlabadi S; Nikpoor AR; Ghaffari S; Attar H; Mashreghi M; Jaafari MR
Anticancer Agents Med Chem; 2020; 20(6):700-708. PubMed ID: 31893998
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models.
Gabizon A; Amitay Y; Tzemach D; Gorin J; Shmeeda H; Zalipsky S
J Control Release; 2012 Jun; 160(2):245-53. PubMed ID: 22134116
[TBL] [Abstract][Full Text] [Related]
9. Carboxylesterases 1 and 2 hydrolyze phospho-nonsteroidal anti-inflammatory drugs: relevance to their pharmacological activity.
Wong CC; Cheng KW; Xie G; Zhou D; Zhu CH; Constantinides PP; Rigas B
J Pharmacol Exp Ther; 2012 Feb; 340(2):422-32. PubMed ID: 22085648
[TBL] [Abstract][Full Text] [Related]
10. A novel size-tunable nanocarrier system for targeted anticancer drug delivery.
Li Y; Xiao K; Luo J; Lee J; Pan S; Lam KS
J Control Release; 2010 Jun; 144(3):314-23. PubMed ID: 20211210
[TBL] [Abstract][Full Text] [Related]
11. Preparation, characterization, and assessment of the antiglioma effects of liposomal celastrol.
Huang Y; Zhou D; Hang T; Wu Z; Liu J; Xu Q; Xie X; Zuo J; Wang Z; Zhou Y
Anticancer Drugs; 2012 Jun; 23(5):515-24. PubMed ID: 22343423
[TBL] [Abstract][Full Text] [Related]
12. Phospho-NSAIDs have enhanced efficacy in mice lacking plasma carboxylesterase: implications for their clinical pharmacology.
Wong CC; Cheng KW; Papayannis I; Mattheolabakis G; Huang L; Xie G; Ouyang N; Rigas B
Pharm Res; 2015 May; 32(5):1663-75. PubMed ID: 25392229
[TBL] [Abstract][Full Text] [Related]
13. Stable and sustained release liposomal formulations of celecoxib: In vitro and in vivo anti-tumor evaluation.
Matbou Riahi M; Sahebkar A; Sadri K; Nikoofal-Sahlabadi S; Jaafari MR
Int J Pharm; 2018 Apr; 540(1-2):89-97. PubMed ID: 29371019
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the Anti-Tumor Activity of Niclosamide Nanoliposomes Against Colon Carcinoma.
Hatamipour M; Jaafari MR; Momtazi-Borojeni AA; Ramezani M; Sahebkar A
Curr Mol Pharmacol; 2020; 13(3):245-250. PubMed ID: 31433764
[TBL] [Abstract][Full Text] [Related]
15. Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts.
Colbern GT; Dykes DJ; Engbers C; Musterer R; Hiller A; Pegg E; Saville R; Weng S; Luzzio M; Uster P; Amantea M; Working PK
Clin Cancer Res; 1998 Dec; 4(12):3077-82. PubMed ID: 9865923
[TBL] [Abstract][Full Text] [Related]
16. Tumor-type-dependent vascular permeability constitutes a potential impediment to the therapeutic efficacy of liposomal oxaliplatin.
Abu Lila AS; Matsumoto H; Doi Y; Nakamura H; Ishida T; Kiwada H
Eur J Pharm Biopharm; 2012 Aug; 81(3):524-31. PubMed ID: 22554766
[TBL] [Abstract][Full Text] [Related]
17. Plasma membrane targeting by short chain sphingolipids inserted in liposomes improves anti-tumor activity of mitoxantrone in an orthotopic breast carcinoma xenograft model.
Cordeiro Pedrosa LR; van Tellingen O; Soullié T; Seynhaeve AL; Eggermont AM; Ten Hagen TL; Verheij M; Koning GA
Eur J Pharm Biopharm; 2015 Aug; 94():207-19. PubMed ID: 25982691
[TBL] [Abstract][Full Text] [Related]
18. Development of a Liposomal Formulation of Acetyltanshinone IIA for Breast Cancer Therapy.
Wang Q; Luo M; Wei N; Chang A; Luo KQ
Mol Pharm; 2019 Sep; 16(9):3873-3886. PubMed ID: 31389706
[TBL] [Abstract][Full Text] [Related]
19. Liposomal formulation of Galbanic acid improved therapeutic efficacy of pegylated liposomal Doxorubicin in mouse colon carcinoma.
Nik ME; Malaekeh-Nikouei B; Amin M; Hatamipour M; Teymouri M; Sadeghnia HR; Iranshahi M; Jaafari MR
Sci Rep; 2019 Jul; 9(1):9527. PubMed ID: 31267009
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and evaluation of a paclitaxel-binding polymeric micelle for efficient breast cancer therapy.
Xiang J; Wu B; Zhou Z; Hu S; Piao Y; Zhou Q; Wang G; Tang J; Liu X; Shen Y
Sci China Life Sci; 2018 Apr; 61(4):436-447. PubMed ID: 29572777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
